MD, State University of New York at Buffalo
BS, Union College

A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus Ritonavir (100mg BID) Versus Lopinavir/Ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg)
08/23/2004 - 04/27/2006 (PI)
GlaxoSmithKline, Inc.

An Open-Label Phase III Study to Access the Long Term Safety Profile of GW433908 Containing Regimens in HIV-1 Infected Adults
05/10/2001 - 06/01/2004 (PI)
GlaxoSmithKline, Inc.

A Randomized Open Label Study of the Antiviral Efficacy and Safety of Atazanavir in Combination with Ritonavir or Saquinavir and the Combination of Lopinavir Ritonavir each with Tenofovir and a Nucleoside in Subjects who have Experienced virologic failure
12/01/2001 - 11/30/2003 (PI)
Bristol-Myers Squibb

A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/ritonavir (700mg/100mg Twice Daily or 1400mg/200mg Once Daily) Versus Lopinavir/ritonavir (400mg/100mg
05/10/2001 - 12/31/2002 (PI)
GlaxoSmithKline, Inc.

An Open-Label Multinational Study of the Effects of Three Dose Pairs of Tipranavir/Ritonavir (BID) on the Pharmacokinetic Characteristics of Protocol Defined, Baseline, Triple Drug Nucleoside and Non Nucleoside Reverse Transcriptase Inhibitor Therapy in H
04/25/2001 - 12/31/2002 (PI)
Boehringer Ingelheim Pharmaceuticals

A Phase IV Multicenter Study of the Efficacy and Safety of 48 Week Induction Treatment with TRIZIVIR (Abacavir 300mg Lamivudine 150mg Zidovudine 300 mg Combination Tablet BID) + Efavirenz (600 mg QD) Followed by Randomized 48 Week Maintenance Treatment wi
03/15/2001 - 12/31/2001 (PI)
GlaxoSmithKline, Inc.

A 24-Week, Randomized, Open-label, Multicenter Trial to Compare the Safety and Efficacy of the Licensed Agenerase Dose (1200 mg BID) to a lower Agenerase dose (600 mg BID) in the presence of Norvir (100 mg BID) when combined with other background antiretr
07/01/2000 - 12/31/2001 (PI)
Kern McNeill International

A Phase III, Double Blind, Randomized, Multicenter Study of the Treatment of Antiretroviral Naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination with Lamivudine and Efavirenz Versus Stavudine, Lamivudine, and
06/16/2000 - 12/31/2001 (PI)
Gilead Sciences, Inc.

A Randomized, Open Label, Phase III Study of ABT/Ritonavir in Combination with Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination with Nevirapine and Two NRTIs in Antiretro
07/21/1999 - 12/31/2001 (PI)
PPD Pharmaco Inc Abbott Laboratories

A Phase IV 48 Week, Randomized, Open Label , Multicenter Trial of Abacavir (300 mg BID)/Efavirenz (600 mg QD)/(Didanosine (400 mg QD) +_ Hydroxyurea (600 mg BID) in HIV-1 Infected Subjects Failing Initial Therapy with Protease Inhibitor/3TC/ZDV (or d4T)
06/01/1999 - 12/31/2001 (PI)
Glaxo Wellcome Inc

Showing 10 of 13 results. Show All Results

American College of Surgeons Oncology Group (ACOSOG) Community Clinical Oncology Program (CCOP) Rese
03/29/2013 - 03/31/2016 (PI)
Mayo Clinic - Rochester NIH-NCI

Master Agreement - Alliance for Clinical Trials in Oncology Case Study Services
03/01/2014 - 02/28/2016 (PI)
Brigham & Women's NIH-NCI

NCCTG Research Base Agreement
04/09/2010 - 12/31/2015 (PI)
Mayo Clinic - Rochester NIH-NCI

Db Study Of Mkc-442
04/01/1998 - 08/31/2008 (PI)

Aids Clinical Trial
01/01/1997 - 12/31/2006 (PI)
Harvard Medical School NIH
5 U01 AI27659-17

Protocol Ftc303
09/21/1998 - 08/07/2005 (PI)

Boston Aids Malignancies Conso
08/01/1996 - 07/31/2005 (PI)
Mass General Hosp DHHS
5 U01 CA071375-09

Aids Clinical Trial
06/16/1999 - 12/31/2000 (PI)
Harvard Medical School

A Phase 1A Open Label Study
05/10/1999 - 12/31/2000 (PI)
Novartis Pharma Corp


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Haigentz M, Moore P, Bimali M, Cooley T, Sparano J, Rudek M, Ratner L, Henry D, Ramos J, Deeken J, Rubinstein P, Chiao E. Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. Oncologist. 2022 Aug 05; 27(8):623-e624. PMID: 35429391; PMCID: PMC9355812; DOI: 10.1093/oncolo/oyac004;
  2. Shah BA, Qureshi MM, Logue JM, Cooley TP, Zaner KS, Jalisi S, Truong MT. Assessing cumulative acute toxicity of chemoradiotherapy in head and neck cancer with or without induction chemotherapy. Am J Otolaryngol. 2017 Jul - Aug; 38(4):456-461.View Related Profiles. PMID: 28427799; DOI: 10.1016/j.amjoto.2017.04.004;
  3. Unger JM, Hershman DL, Arnold KB, Loomba R, Chugh R, Hwang JP, O'Rourke MA, Bhadkamkar NA, Wang LX, Siegel AB, Cooley TP, Berenberg JL, Bridges BB, Ramsey SD. Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol. 2016 May; 12(10):1219-31. PMID: 26952901; PMCID: PMC4864045; DOI: 10.2217/fon-2015-0076;
  4. Shah BA, Qureshi MM, Jalisi S, Grillone G, Salama A, Cooley T, Zaner K, Sakai O, Truong MT. Analysis of decision making at a multidisciplinary head and neck tumor board incorporating evidence-based National Cancer Comprehensive Network (NCCN) guidelines. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):248-54.View Related Profiles. PMID: 26777060; DOI: 10.1016/j.prro.2015.11.006;
  5. Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 1; 121(3):423-31. PMID: 25251326; DOI: 10.1002/cncr.29066;
  6. Qureshi MM, Romesser PB, Jalisi S, Zaner KS, Cooley TP, Grillone G, Kachnic LA, Truong MT. The influence of limited English proficiency on outcome in patients treated with radiotherapy for head and neck cancer. Patient Educ Couns. 2014 Nov; 97(2):276-82.View Related Profiles. PMID: 25190640; PMCID: PMC5014351; DOI: 10.1016/j.pec.2014.07.031;
  7. Yu J, Cooley T, Truong MT, Mercier G, Subramaniam RM. Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters. J Med Imaging Radiat Oncol. 2014 Feb; 58(1):18-24.View Related Profiles. PMID: 24529051; DOI: 10.1111/1754-9485.12081;
  8. Boehmer U, Cooley TP, Clark MA. Cancer and men who have sex with men: a systematic review. Lancet Oncol. 2012 Dec; 13(12):e545-53.View Related Profiles. PMID: 23182195; DOI: 10.1016/S1470-2045(12)70347-9;
  9. Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A. Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047. J Clin Oncol. 2013 Jan 1; 31(1):58-64. PMID: 23169503; PMCID: PMC3530691; DOI: 10.1200/JCO.2012.42.4648;
  10. Agarwal A, Mehta A, Logeswaran P, Cooley TP, Subramaniam RM. Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity. Arch Otolaryngol Head Neck Surg. 2012 Sep; 138(9):869-70. PMID: 22986725; DOI: 10.1001/archoto.2012.1675;
Showing 10 of 47 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Education Mentor
  • Research / Scholarly Mentor
Contact for Mentoring: